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Abstract
The aim of this systematic review is to describe and assess the quality of the existing evidence base
concerning factors that influence the compliance of cat and dog owners to pharmaceutical and
specifically polypharmacy treatment recommendations.
PubMed, CAB Abstracts and Google, were searched to identify relevant literature and search results
were filtered according to pre-determined inclusion and exclusion criteria. Standardised data
extraction and critical appraisal was carried out on each included study and a Centre for Evidence-
Based Medicine (CEBM) level of evidence grading applied.
Of the 8589 studies, 8 studies were included in the review. The majority (5/8) of the included studies
were examining compliance with short term antimicrobial therapies and none examined
polypharmacy. Multiple definitions of compliance, methods of measurement, and different factors
potentially affecting compliance, were used. Factors reported to have affected compliance in at least
one study were; the dosing regime, discussion of the dosing regime in light of the owners
circumstances, consultation time, the disease, the month of the consultation/treatment, physical risk,
social risk, and method of administration.
The evidence available regarding factors affecting client compliance with pharmaceutical treatment
recommendations in cats and dogs is scarce and of poor quality.
Introduction
Numerous medications are widely available to small animal practitioners and their clients, with many
conditions now having multiple licensed and unlicensed therapies that can alleviate signs of disease.
How well owners comply with, or adhere to, treatment recommendations made by veterinary
surgeons can significantly affect the success of using these medications and the subsequent health
outcomes for the patients. Compliance can be described as:
2‘the consistency and accuracy with which a patient follows the regimen prescribed by a
physician or other health care professionals’ [Stedman’s online medical dictionary;
www.stedmans.com]
Compliance (and adherence) includes not only whether the medication is administered, but also the
accuracy of the dose that is administered and whether the patients receive it ‘on time’. In order to
maximise compliance, it is important to understand the factors affecting whether a client will comply
with the recommendations made by the veterinarian. The factors affecting compliance may also vary
depending on the specific condition being treated, the duration of treatment required and whether
multiple medications are prescribed, amongst other things. Understanding this complex phenomenon
could provide opportunity to alter behaviours of both the prescriber and the client, improve compliance
and ultimately improve the health of the patients.
Many systematic reviews have been undertaken in human medicine attempting to assess what
factors affect compliance, with a view to implementing effective intervention strategies to improve it.
Compliance research in the medical field has been carried out across various conditions, including
those that require polypharmacy, and many different types of interventions have been tested including
simplified dosing regimens, patient education and support, medication reminders, limiting economic
impacts on the patient and drug formulation 1-4. Overall, there have been very few proposed
successful interventions for improving compliance amongst medical patients2, with simplified dosing
regimens, coverage of prescription costs and educational interventions having shown some positive
effects on compliance3,5 4 across different disciplines. It is unclear if the factors affecting compliance in
medical patients translate to the compliance behaviour of veterinary clients and their pets.
A systematic review of this topic is the first of its kind in veterinary medicine and will provide a good
understanding of the evidence base regarding factors affecting client compliance with pharmaceutical
treatment recommendations in small animal practice; it is a crucial first step in being able to improve
compliance.
Aims
To describe and assess the quality of the existing published evidence base concerning factors that
influence the compliance of cat and dog owners to pharmaceutical treatment recommendations by
veterinary prescribers.
A secondary aim is to describe and assess the quality of the existing published evidence base
concerning factors that influence the compliance of cat and dog owners to polypharmacy
pharmaceutical treatment recommendations by veterinary prescribers.
Materials and methods
3Search strategy
To identify relevant literature, strategic searches using keywords and subject headings were
performed in Medline and CAB Abstracts literature databases (February 2016) using OVID and in
Google (April 2016); search terms used can be found in Table 1.
Table 1: Search terms used to search MEDLINE and CAB Abstracts (OVID) literature databases
and Google
Search location Search terms
Ovid MEDLINE® In-Process & Other
Non-Indexed Citations and Ovid
MEDLINE® 1946 to present
(cat.mp. OR cats.mp. OR feline.mp. OR felines.mp.
OR felis.mp. OR exp cats/ OR dog.mp. OR
dogs.mp. OR canine.mp. OR canines.mp. OR
canis.mp. OR exp dogs/ OR veterinary.mp. OR exp
veterinary medicine/)
AND
(Complian*.mp. OR adher*.mp. OR
concordan*.mp. OR exp patient compliance/ OR
exp medication adherence/)
CAB Abstracts 1910-2016 (cat.mp. OR cats.mp. OR feline.mp. OR felines.mp.
OR felis.mp. OR exp cats/ OR dog.mp. OR
dogs.mp. OR canine.mp. OR canines.mp. OR
canis.mp. OR exp dogs/ OR veterinary.mp. OR exp
veterinary medicine/)
AND
(Complian*.mp. OR adher*.mp. OR
concordan*.mp. OR exp patient compliance/)
Google (www.google.co.uk) (cat OR cats OR feline OR felines OR felis OR dog OR
dogs OR canine OR canines OR canis OR veterinary)
AND
(compliance OR compliant OR adherence OR
adhere OR adhering OR adherent OR
concordance OR concordant)
Filtering of search results
Search results from CAB Abstracts and MEDLINE literature databases were imported into Endnote
for sorting. Duplicates were removed and results filtered by title and abstract screening, followed by
full text screening when required, according to the inclusion and exclusion criteria in Table 2. Two
authors (KW and RD) filtered all the results from these searches independently. The first 800 hits in
the Google search were filtered ‘live’ in Google by two authors (KW/RD) together, according to the
same inclusion and exclusion criteria. For all sorting, a third author (MB) resolved any disagreements.
Foreign language papers that were not excluded by title/abstract screening were read by a translator
to check for relevant content. Full text translation was performed if necessary to determine whether
the article fulfilled the inclusion criteria.
Data extraction from included studies
4Data extraction on the included studies was performed using a standardised Excel form by one author
(KW) and verified by a second author (RD/MB), disagreements were resolved by discussion.
Information extracted included; study design, study setting, sample size, sample description, whether
polypharmacy was used, the main findings of the study, factors affecting compliance proposed from
the study, factors affecting compliance tested in the study and their effect on compliance.
Quality assessment of included studies
Critical appraisal of the included studies was performed using standardised critical appraisal
checklists in use at the Centre for Evidence-based Veterinary Medicine (CEVM;
www.nottingham.ac.uk/cevm). The corresponding checklist was used for each study type as
appropriate; the critical appraisal checklist most appropriate to the compliance aspect of the study
was used, regardless of the main aim of the study (e.g. if the main study was a randomised controlled
trial (RCT) examining efficacy, but the compliance aspect of the report was a descriptive study, the
standard critical appraisal checklist was used instead of the RCT checklist). The completed critical
appraisals were used to identify any study weaknesses. Critical appraisal was performed by one
author (KW) and verified by a second author (RD/MB) with disagreements resolved by discussion.
Grading of the included evidence
The level of evidence provided by included studies where factors potentially affecting compliance
were tested was determined using The 2011 Centre for Evidence-Based Medicine (CEBM) grading
system6-8. Included studies where factors potentially affecting compliance were described or proposed
from the data, as opposed to tested, were not graded.
Table 2: Inclusion and exclusion criteria for filtering search outputs
Criteria Inclusion Exclusion
Population of
interest
Owners of cats and dogs when a
pharmaceutical agent is being
recommended for therapeutic effect by
a veterinary prescriber and is to be
administered at home
Large animal and equine clients, small
animal clients not relating to cats and
dogs
Medical practice
Therapeutic agents being used
prophylactically i.e. preventive medicine
Prescription diets
Therapeutic agents to be administered
in clinics or by veterinary staff
Outcome Contain an assessment, or description,
of factors affecting
compliance/concordance/adherence to
veterinary therapeutic treatment
recommendations relating to dogs and
cats
Do not contain an assessment or
description of factors affecting
compliance/concordance/adherence to
veterinary therapeutic treatment
recommendations relating to dogs and
cats
5Publication
type
Full study reported
Peer-reviewed published literature
Abstracts only
Non peer-reviewed published literature
Grey literature
Conference proceedings
Book chapters
Theses
Study type * Randomised controlled trials
Cohort studies
Cross-sectional studies
Case reports/series
Qualitative studies
Narrative reviews
Availability Able to obtain through University Of
Nottingham library or inter-library loan,
or by direct request to authors
Unable to obtain full manuscript
Language All languages
*Study type definitions in Supplementary Material 1.
Results
Literature searches and filtering
CAB Abstracts and MEDLINE searches returned 2405 and 6184 papers respectively, giving a total of
8589 papers. 1109 duplicates were removed leaving 7480 papers to be filtered by title/abstract/full
text screening. 7472 papers were excluded, therefore, eight studies fulfilling the inclusion criteria
remained in this review. Of the 800 hits filtered in the Google search, 795 were duplicates or excluded
and the five remaining articles were already included from the CAB Abstracts and MEDLINE
searches; see Figure 1 for a flow diagram of the search results and filtering process.
Main characteristics of the included studies
The summary characteristics of all included trials are displayed in Table 3 (Supplementary Material 2).
Of the eight included studies, all but one were directly examining owner compliance, and the factors
associated with owner compliance, with therapeutic treatment recommendations in cats and dogs in a
small animal practice setting. The remaining study was an efficacy study which also reported some
indicators of owner compliance. None of the included studies examined polypharmacy or multimodal
therapies. Regarding the compliance aspects of the studies, the included studies comprised two
RCTs, three cohort studies, one case series and two cross sectional questionnaire studies, with one
of the RCTs additionally including a cross sectional questionnaire.
The majority of the studies (5/8) examined compliance with short term administration of anti-microbial
medications, one of these being topical administration for otitis externa9, the remainder being oral
antibiotics for acute bacterial infections10-13. One study examined compliance with treatment for atopy
(hypo sensitisation by allergen injection)14, one for mammary neoplasia15, and the therapeutic area of
the remaining study was not identified16. The longest treatment periods and follow up of compliance
were in the atopy study where compliance was examined from commencement of treatment to a
6maximum of seven years. Only one study included cats and their owners16, the rest exclusively
related to dogs. Compliance levels were measured using a range of different methods across the
eight studies including owner self-reporting of missed doses, pill counting, electronic medication
monitoring, and reviewing repeat medication orders.
Main findings of the included studies
The main findings of each included study, including the level of client compliance observed, can be
found in Table 3. Levels of compliance were very dependent on the measurement methods
employed, and the definition of compliance used in the study.
Six of the studies9,11,13,14,16,17 tested factors potentially affecting compliance in our target population;
within these a large number of different factors were tested. The tested factors, along with whether
they influenced compliance or not, can be found in Table 4. Of the factors tested, the following were
reported to have affected compliance in at least one of the included studies; once versus three times
daily dosing, twice versus three times daily dosing, discussion of the dosing regime in light of the
owners circumstances, consultation time spent with the vet, the disease condition being treated, the
month of the consultation/treatment, physical risk, social risk, and product pump administration once
daily for 5 days compared to standard drops twice daily for seven days for topical treatment of otitis
externa in dogs.
There were very few identical factors tested across more than one study. Twice versus three times
daily dosing was tested as a factor in three of the studies with conflicting results. One cohort study
reported that three times daily dosing compared to twice reduced compliance17, compared to one
small RCT and one cohort study reporting there was no difference in compliance11,13. The specific
disease condition being treated also produced conflicting results; with an influence on compliance in
one cohort study (treatment of gastrointestinal infections was associated with higher compliance
levels than wound infections13) but no effect in another17. Similar factors tested in more than one
study but which unanimously had no effect on compliance were: route of administration of medication,
treatment outcome/effect of treatment, owners employment in relation to the dosing regime and
whether the owner knew what disease was being treated.
The remaining two studies12,15 only proposed factors arising from the data that could influence client
compliance as opposed to testing them. Two of the six studies9,14 described above, also proposed
factors affecting client compliance in addition to the factors that were tested. These proposed factors
can be found in Table 5.
7Table 4: Summary of results, study weaknesses and evidence level grading of included studies where potential factors affecting compliance were tested,
N=6.
Study reference Factors affecting compliance tested in the study Affected
compliance
(Yes/No/Described
only/No results
reported)
Study weaknesses Evidence level
grading
Adams et al, 200517. Number of daily doses 1 vs 2
Number of daily doses 1 vs 3
Number of daily doses 2 vs 3
Discussion of dosing regime in light of client
circumstances
Severity of disease – according to vet
Treatment outcome
Specific drug prescribed
Length of treatment
Specific disease condition – according to vet
Pet very important to client
Client and pet close relationship
Veterinarian prediction of compliance
Specific disease condition – according to client (whether
they could name it
Member of family closest to pet
Member of family giving most medication
Trouble giving medication to pet - client reported
How did you give medication - e.g. mouth/food
Missing a dose due to work a problem for you
Strength of vet-client-patient relationship
Human animal bond
Number of doses reported missed by owner
No
Yes
Yes
Yes
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
 Lack of details given on how
some of the exposures data
were obtained
 No justification of the sample
size used
 Some subjective outcome
measures and reliance on
self-reporting of clients for
some measures
 Subjective reporting of some
exposures with no validation
provided
 Not all variables tested for
effect on compliance fully
discussed
 Enrolment was intended to
be consecutive cases but
ended up being a
convenience sample
potentially introducing
selection bias
 Pharmaceutical funding
CEBM level 3
Barter et al, 199611. Twice versus three times daily dosing No  No details given on how
randomisation was
performed
 No information on whether
allocation concealment or
blinding was performed
 No justification of the sample
size and small sample size
used
CEBM Level 2
8 Very brief description of
statistical methods and no
statistical significance level
stated in the methods
 Pharmaceutical funding
Boda et al, 20119. Product pump administration once daily for 5d compared
to standard drops twice daily for 7d
Yes  No details given on how
randomisation was
performed
 No justification of the sample
size used
 No blinding used
 No statistical significance
level stated in the methods
 No funding source stated
 Pharmaceutical company
involvement (author
employment)
CEBM Level 2
Grave et al, 199913. Consultation (time spent with vet)
Information about use of drug
The disease condition
One tablet twice daily versus one tablet three times daily
(treatment regimen)
Effect of treatment
Administration of tablets (route)
Owner perception of severity of disease
Owners employment (relation to dosing regimen)
Size of dog
Start of treatment (how soon after consultation)
Owners knowing the disease being treated
Consulting/treatment month
Yes
No
Yes
No
No
No
No
No
No
No
No
Yes
 Reliance on self-reporting
from clients for compliance
determination
 Lack of detailed information
on how the telephone
interviews were conducted
and therefore how exposures
were measured
 No justification of the sample
size used
 Numbers presented in
results don’t always add up,
difficult to follow all subjects
through the study
 No funding source stated
 No effect sizes presented
 No discussion of potential
confounding factors
CEBM Level 3
Maille et al, 201316. Physical risk
Social risk
Yes
Yes
 Lacking in details on
methods especially
questionnaire content
 Lack of detail on the
characteristics of the
participating owners/animals
e.g. what treatment was,
Unclear
9duration of treatment etc
making it difficult to be able
to apply the information to a
population
 No justification of the sample
size used
 Statistical significance level
not stated in the methods
 Lack of full reporting of basic
data makes it hard to follow
subjects through the study
Saevik et al, 200214. Owners awareness that induction was 9 months
Owners awareness that treatment would be lifelong
Described only
Described only
 Unclear if all eligible subjects
were included in the study
 Likely to be high chance of
recall bias due to long
durations of treatment
 Lack of detail regarding what
information was collected at
owner interviews
 No statistical analysis of the
data, no estimate of effect
size given
 No justification of the sample
size used
CEBM Level 3
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Table 5: Summary of results and study weaknesses of included studies where potential factors affecting compliance were described, N=4.
Study reference Factors potentially affecting compliance identified in the
study
Study weaknesses
Boda et al, 20119. Wrong duration/frequency of treatment applied
Difficulty in applying the right dose
Misunderstanding of the medical condition
Reliability of the owner
Satisfaction with positive features of the product Dissatisfaction with
negative features of the product
Satisfaction with duration of treatment
Satisfaction with frequency of treatment
Global satisfaction with the product
Satisfaction with ease of use of the product (by veterinarians)
 Questionnaire subjective and not validated
 Not enough detail provided about the questionnaire
itself
Bomzon et al, 197812. Unable to comply with instructions due to being at work during the day  Subjective questioning of owners
 Lack of full discussion on possible factors affecting
owners responses to questioning
Morris et al, 199315. Owner refusal (after initial consent)
Animal unwell
 Aim of the study not relating to compliance therefore
study not designed to specifically assess compliance
 No details on questioning of owners, unclear how data
relating to compliance was obtained
Saevik et al, 200214. No noticeable improvement
Good response
Worsening of problem
Allergens too expensive
Unable to give the dog injections
Difficulty in obtaining renewal orders
Unrelated illness/death
Too time consuming
Change of owner
 No details on how owners were questioned to obtain
the information
 Likely risk of recall bias due to long durations of
treatment
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Quality assessment of the included studies
All eight of the included studies were critically appraised and their study weaknesses can be found in
Tables 4 and 5. The six studies which tested factors potentially affecting client compliance were
assigned a CEBM level of evidence grading based on their study design and quality. There were no
Level 1 (highest level e.g. systematic reviews) sources of evidence found with our searches. The two
RCTs were assigned as evidence grading level 2, the three cohort studies were graded as level 3
evidence, and the cross sectional questionnaire as ‘unclear’. In terms of key quality criteria, both
RCTs 9,11 failed to report how randomisation was performed, whether allocation concealment was
ensured and whether blinding was employed. The cohort studies10,18,19 all lacked detail in how
exposures and outcomes were measured and largely relied on subjective measurements. All the
included studies failed to report a sample size calculation, or a justification of the sample size that was
used.
Discussion
This is the first systematic review of the veterinary literature examining cat and dog owner compliance
with veterinary therapeutic recommendations. Overall, 8 studies were found that could be included in
this review with varying study designs and qualities. The majority of the studies examined short term
compliance with antimicrobial therapies with the only chronic treatment examined being
hyposensitisation injections for atopy in dogs. Actual levels of client compliance varied depending on
how compliance was defined and measured. The included studies were not similar enough in design,
or population studied, to be able to produce one overall combined estimate of the level of client
compliance observed.
The majority of the factors potentially affecting compliance that have been tested within the studies in
this review, have only been tested in one randomised controlled trial or cohort study (Level 2 or 3
evidence), and all have significant methodological weaknesses that could have biased their results.
For the two factors that demonstrated an effect on compliance and were tested in more than one
study, there were conflicting results and without further evidence it is difficult to assert with any
strength any changes that could be implemented to improve client compliance in our target
population.
Client compliance with recommended therapies is an important factor in the success of treatments
and can heavily influence outcomes in our patients. The varying levels of compliance reported in the
studies in this review are also seen in the medical literature where adherence rates average around
50%, but range from 0% to over 100%2. One of the major problems highlighted by this review in
examining compliance is the differing ways in which it is defined and measured. A consensus on a
veterinary definition and accepted level of defining ‘compliant clients’ would be beneficial going
forwards in this field of research, for example, the medical literature often defines non-adherence as
taking less than 80% of prescribed doses2. Consistency in how compliance is measured, with less
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reliance on subjective measures, would also be beneficial. Studies which assess compliance
alongside clinical outcomes are also required to further our knowledge in this field, as it is difficult to
truly gauge any positive impact of an intervention strategy on patients without measuring both2.
In addition to a lack of consistency in defining compliance, there was a wide range of descriptions of
the factors being tested in the included studies making combining and comparing the results to
produce meaningful recommendations very difficult. The overall large number of different factors
being tested is understandable given the broad nature of the topic and the lack of current knowledge
on which factors are potentially important, but unfortunately this means that the evidence base on any
one factor is very limited. Also, some of the factors being tested across studies potentially have the
same meaning but are described differently and therefore cannot be directly compared. Some of the
proposed factors that could potentially affect client compliance have been extrapolated from human
literature and then tested in a veterinary setting. It can not be assumed the two settings are the same
but in certain circumstances where carers are involved in helping patients take medications (e.g.
paediatrics) in human healthcare the issues around compliance may be more similar to veterinary
medicine.
Some of the factors being tested in these studies have been tested in human compliance studies,
including dosing regimen. In this review, once or twice daily dosing compared to three times daily
dosing was found to positively impact on compliance in one of the included studies, but not in two
others. Reducing the number of daily doses to improve compliance has also been tested in human
compliance studies with positive effect 4,5. The two cohort studies within this review that tested twice
versus three times daily dosing with conflicting results were both reasonably large (90 and 95
participants) and both had some methodological weaknesses; the randomised controlled trial
reporting no effect on compliance of this factor was very small (22 participants). One of the cohort
studies finding positive impact of once or twice daily dosing compared to three times daily dosing
additionally found no positive effect on compliance of reducing twice daily dosing to once daily 17; this
was hypothesised to be due to the small sample size of dogs being prescribed once daily medication.
It was additionally proposed by the authors of the study that missing one dose when on a once daily
regime could potentially have more negative impact that missing one dose whilst on a twice daily
regime17, another factor to be considered when examining effects of compliance. A further, larger
randomised controlled trial examining the effect of dosing regimen on client compliance would be very
beneficial in determining optimum dosing regimens for client compliance.
Many conditions for which we prescribe treatments in veterinary work require more than one
therapeutic agent for treatment, especially in chronic disease, or older animals with multiple co-
morbidities. We found no relevant evidence in our review relating to client compliance with
polypharmacy treatment recommendations in dogs and cats. In humans, polypharmacy has been
associated with reduced compliance rates in elderly patients20, but a recent systematic review
highlighted the fact that there was scarce evidence on the topic and no significant benefits of any one
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approach to improving compliance in such a setting was identified 21. One potentially promising
strategy aimed at improving compliance with polypharmacy in human cardiovascular medicine is the
‘polypill’, or fixed dose combination therapy. This is where multiple cardiovascular therapies have
been combined into one single daily pill; this has recently been trialled and so far has been shown to
have positive effects on both adherence and some clinical outcomes 22. More work on this area is
required in the human field and is a potential avenue that could be explored in the veterinary field in
the future.
In extracting the results from, and assessing the quality of, the studies included in this review, one of
the major problems encountered was a lack of sufficient reporting of details concerning how data was
collected and analysed, and how results have been described. Reporting deficiencies, such as failing
to report how randomisation of participants was performed, are a common problem identified in both
medical and veterinary literature and it has been shown many times that such deficiencies can heavily
influence the results of a study23-26. Through failing to report how randomisation was performed, and
whether allocation concealment and blinding were ensured, the RCTs in this study are open to risks
of selection bias and performance bias which could have influenced their results. In some cases,
studies may actually be methodologically sound, but unless sufficient information is reported it is
impossible to assess27,28. The use of reporting guidelines when writing up research studies, such as
the CONSORT checklist for randomised controlled trials29 and the STROBE checklist for
observational studies30, should help to improve this situation. The endorsement of, and requirement to
use, these guidelines by journals could further this potential impact.
Limitations of the study
CAB Abstracts and MEDLINE literature databases were searched as we know from previous research
that these give us good coverage (over 90%) of the veterinary literature31. An additional Google
search helped to ensure that other potential sources of evidence relevant to our objective would be
identified but there is always the possibility that relevant literature exists that was not found and
therefore included in this review. Time and financial constraints limited searching to major databases
and Google and necessitated the exclusion of grey and non peer-reviewed literature from this review
which could have an impact on our findings. It is also possible relevant evidence has been missed
due to the nature of the information we were looking for in this review; compliance may have been
studied but if it was not the main focus of a study it would potentially not be mentioned in the title and
abstract of a manuscript. It was not possible to read the full text of all articles found in the searches in
order to identify such evidence. We have not looked for the presence of publication bias and
assessed any impact this may have had on our review. Time and financial constraints also limited us
to one author performing data extraction with a second verifying the findings, rather than two authors
independently extracting data. This review has focused on client compliance with the administration of
therapeutic pharmaceuticals in dogs and cats, there is however further evidence available concerning
compliance in other veterinary fields e.g. preventive medicine, dental treatment, and in other species,
which may contain useful information that can be applied across disciplines32-34.
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Conclusion
Overall, there is very limited evidence, in both quantity and quality, concerning the factors affecting
client compliance with therapeutic pharmaceutical treatment recommendations in cats and dogs, and
no evidence at all was found to address our second aim concerning compliance with polypharmacy.
The lack of evidence does not mean there is no possibility of improving compliance and it is important
that the knowledge base is improved. Further studies specifically aimed at examining and testing
factors affecting compliance in veterinary practice would be extremely beneficial to further our
knowledge and understanding of how best to maximise compliance and subsequently improve the
health of our patients. In particular, relevant to our second aim, studies are required to examine how
compliance is affected when multiple therapies are needed to treat chronic diseases commonly seen
in companion animal practice. The further research needed includes both qualitative studies to
explore and propose the factors affecting client compliance, along with randomised controlled trials to
test factors affecting compliance. Qualitative studies allow us to identify which factors are potentially
important to client compliance without making assumptions which could well be incorrect, the
proposed factors can then be tested formally in randomised controlled trials. Whilst some factors
affecting compliance may be important across all situations, it is possible that situation specific details
including the disease condition itself, severity of the disease, type of treatment, and chronicity of
treatment would have differing effects on compliance and would require differing approaches. This
raises the potential need for future research studies to address specific situations in order to generate
meaningful information that could be successfully used in practice.
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Main findings of the study
Adams et
al, 200517.
Yes Cohort
study
North America,
September
2000-August
2001, one
veterinary
teaching
hospital and 9
clinics in 3 cities
90
clients/dog
s
Convenience
sample of
dogs requiring
short term
antimicrobial
administration
(the type,
dosage,
regimen and
duration of
treatment was
at the
veterinarians
discretion),
Clients must
have visited
the clinic
before to be
eligible,
owners were
not aware
compliance
was being
assessed at
the start of the
study,
 Return
mediation pill
count
 Client self-
reporting of
missed doses
 Electronic
medication
monitoring
 Veterinarian
prediction
Anti-
microbial
(acute
bacterial
infections)
No Degree of client compliance depended on
the definition and method of assessment -
all methods of assessment used were
significantly different from each other
(p<0.003) except for client self-reporting of
missed doses and pill count (p>0.05).
Compliance levels using different
assessment methods were:
1. Pill count: 80% of clients had
100% compliance.
2. Client self-reporting of missed
doses: 74% of clients reported
100% compliance.
3. Electronic monitoring device data:
Percentage of bottle openings:
48% had 100% compliance.
Percentage of days correct
number of doses given: 42% had
100% compliance. Percentage of
doses given on time: 20% had
100% compliance.
4. Veterinarians predicted 81% of
clients (72/89) would be compliant
or highly compliant, 3 clients
would be non-compliant and 14
clients would be neither compliant
nor non-compliant.
Clients were significantly more compliant
with once/twice daily dosing compared to
three times daily dosing (OR* for being
100% compliant for 1x or 2x daily
compared to 3x daily = 2.2, p=0.004).
Discussion of dosing regime in light of client
circumstances significantly improved
compliance (OR for being 100% compliant
= 2.5, p<0.0001).
Barter et al,
199611.
Yes Randomise
d
controlled
trial
Sydney,
Australia: 3
inner city
veterinary
practices
22
clients/dog
s
Dogs with
acute,
uncomplicated
bacterial
infections, in
first 5-7 days
of treatment,
not receiving
any other
medical
treatments -
owners
agreeable to
participation.
Owners were
not aware
compliance
was being
assessed at
the start of the
study.
 Electronic
monitoring
(EMR) - used
to determine
doses given
(%), optimum
interval, doses
per day
Antimicrobi
al
(amoxicillin
-
clavulanate
only for
acute
bacterial
infections)
No There was no significant difference in
compliance assessed by ‘mean doses
given’ between twice (BID) and three times
(TID) daily dosing (TID 92%, BID 76%,
median for both groups 93%, p>0.05).
Average of 32% of doses given within
optimum time periods, there was no
significant difference between dosing
regimens (BID 43%, TID 22%, p>0.05).
Number of doses per day correctly
administered on 56% of days for BID and
59% of days for TID (no statistical
comparison).
The mean proportion of all doses given was
84% with the exact prescribed number of
doses being given by 6/22 owners (27%). 1
owner was overcompliant (gave an extra
dose). 15/22 (68%) owners gave less than
the prescribed number of doses. 4/22
owners (18%) gave less than 80% of
prescribed doses.
Boda et al,
20119.
Yes Randomise
d
controlled
trial and
7 veterinary
practices in
France and
Germany
42
clients/dog
s
Dogs of
various breeds
presenting for
bilateral acute
 Weight of
returned
product used
to determine
Antimicrobi
al and anti-
inflammator
y (otitis
No No significant difference between owner
reported missed doses between the two
treatments (p=0.4615).
cross
sectional
questionin
g of
owners
otitis externa,
none had
received any
treatment in
the previous 7
days.
Owners were
not aware
compliance
was being
assessed at
the start of the
study.
compliance
ratio (number
of actual
doses
administered
by owners)
 Owner
questionnaire
by phone to
determine
self-reporting
of missed
doses
 Vet reporting
of predicted
owner
compliance
externa;
topical
preparation
)
Percentage of non-compliant owners based
on compliance ratio was 21.1% (4/19) for
Easotic and 78.9% (15/19) for Surolan.
Variance of the compliance ratio was
significantly different between treatments
(Easotic compliance ratio 1.06+/-0.35;
Surolan compliance ratio 0.8 +/=0.68; p =
0.008).
Difficulty in applying the right dose was
reported by 0/4 non-compliant owners in
the Easotic group and 14/15 in the Surolan
group.
Misunderstanding of the medical condition
was reported by 2/4 non-compliant owners
in the Easotic group and 5/15 in the
Surolan group.
Bomzon et
al, 197812.
Yes Case
series and
cross
sectional
questionin
g of
owners
2 month period
in a small animal
practice in South
Africa
26
clients/dog
s
Dogs with
acute bacterial
infections that
could be
treated with
ampicillin -
prescribed 3
times daily for
5-7d
Owners were
not aware
compliance
was being
assessed at
the start of the
study.
 Measurement
of remaining
medicine
Antimicrobi
al
(ampicillin
only for
acute
bacterial
infections)
No 25/26 prescriptions were issued within 30-
90 minutes of the consultation, the
remaining one was completed the next day.
Overall 73% of owners (19/26) did not
adhere to instructions: 50% of owners
(13/26) had more antibiotic left than they
should have, 23% (6/26) had less
remaining than they should have and 27%
(7/26) had the correct amount remaining.
All underdosing owners cited the reason for
underdosing as being that they were unable
to comply with instructions due to being at
work during the day.
Grave et al,
199913.
Yes Cohort
study
Outpatient
department at
Norwergian
college of
veterinary
medicine (dogs
95
clients/dog
s
Dogs suffering
from acute
bacterial
infections
treated with
either TMPS
 Pill count
performed by
owners -
information
gathered by
telephone
Antimicrobi
al (acute
bacterial
infections)
No 100% compliance was exhibited by 44% of
95 owners/animals. 25% had 90-100%
compliance and 19% had 80-90%
compliance. 12% had a compliance rate
that was less than 80%.
enrolled when
run as a private
clinic in the
evenings); 7
month period
(Sept to March)
tablets 2x day
or
phenoxymethy
lpenicillin 2-3x
day for 10
days. Supplied
with a
prescription
which had to
be obtained
from a
pharmacy.
Person
attending clinic
had to be one
giving
medication to
be enrolled.
Excluded (18)
if didn't obtain
prescription or
answer all
questions.
Owners were
not aware
compliance
was being
assessed at
the start of the
study.
interview. 85% of owners felt the vet had spent
enough time in consultation, this was
associated with a significantly higher
compliance rate than those not thinking
they spent enough time (p<0.002).
Lower compliance was found in January
compared to other months (p<0.004).
Animal owners were significantly more
compliant when the animal was being
treated for a gastrointestinal infection than
for wound infections (p<0.05).
18% (17) reported problems giving tablets
at scheduled times due to employment but
this was not associated with lower
compliance (p=0.07).
91/95 owners were familiar with the
indication for use of the prescribed drug -
no effect on compliance.
18 owners felt the condition was severe, 26
owners moderate and 57 mild - no effect on
compliance.
22 started treatment on the day of
consultation, 70 on first day after
consultation, one on second day and 2 on
the 3rd day after consultation - no effect on
compliance.
No other factors tested had any effect on
compliance.
Maille et al,
201316.
Yes Cross
sectional
questionna
ire
France, owners
of dogs and cats
completing
questionnaire in
vet waiting
room/pet
cleaning
facility/pet
413
owners of
dogs and
cats
Animals
currently
undergoing
treatment or
having ended
treatment less
than 15 days
previously.
 Questionnaire
determined
compliance
Not stated Unclear There was a significant influence of
physical and especially social risk on
compliance (p<0.01).
Those with higher trust in the vet perceive
physical risk (dz taking longer to cure,
chance of fatality) as stronger (p<0.001).
Those with high trust in the vet compared to
shop/public
garden/hyperma
rket pet
department or
street.
low trust have a stronger positive influence
of perceived physical risk (p<0.01), under
these circumstances physical risk becomes
more determinant than social risk.
Physical risk influences those with high and
low attachment to their pet (p<0.01), but
influences those with high attachment most,
again under such circumstances physical
risk becomes more important than social
risk.
Morris et al,
199315.
No Cross
sectional
questionin
g of
owners for
compliance
during trial.
RCT for
tamoxifen
vs no
treatment.
General
practices within
10 mile radius of
Cambridge Vet
School
submitted
samples
(excised
mammary
masses) for
histopathology
between April
1991 and
December 1992.
Spayed bitches
with
benign/malignan
t tumours then
included in
ongoing trial
comparing
tamoxifen and
no treatment.
93 bitches
enrolled -
only 51
spayed
and eligible
to enter
drug trial
51 spayed
bitches with
benign/malign
ant excised
mammary
tumours
randomised to
receive
tamoxifen or
no treatment.
 Not reported Oncology No 5/23 randomised to tamoxifen failed to
comply - reasons were: owner refusal after
initial consent (3), animal unwell (1) and
animal was euthanased before treatment
began (1).
Saevik et
al, 200214.
Yes Cohort
study
Norway referral
practice
130
clients/dog
s
Dogs
hyposensitised
between June
1997 and June
1999, various
breeds and
mixed breeds,
sexes and
ages. Dogs
 Review of
ordering forms
for
hyposensitisati
on mix
 Telephone
interviews with
owners
NB
Dermatolog
y
No Telephone interviews were completed for
121 dogs (93.1%). 80 dogs (66.1%) treated
for at least 9 months; 22.3% (27/121)
discontinued after 3 months, 11.6%
(14/121) after 6 months, 21.5% (26/121)
after 9 months and 14.9% (18/121) after
12-21 months. 54 dogs (44.6%) had
maintenance injections ordered for them.
81% of owners gave the injections at home.
diagnosed as
atopic and
undergone
allergen
testing,
referring
clinicians
prescribed
immunotherap
y. Group1:
dogs treated
with
immunotherap
y for
<9months,
Group 2: dogs
treated with
immunotherap
y for at least 9
months (max 7
years).
Discontinuatio
n of treatment
in the 9 month
induction
period
recorded as
non-
compliance
Reasons for discontinuing treatment within
9 months given as: No noticeable
improvement, good response, worsening of
problem, allergens too expensive, unable to
give the dog injections, difficulty in
obtaining renewal orders, unrelated
illness/death, too time consuming, change
of owner.
48.8% of owners in group 1 were aware of
9 month induction period compared to
82.5% in group 2. 29.3% of owners were
aware treatment would be lifelong in group
1 compared to 30% in group 2. 31.7%
(13/41) discontinued without approval from
their vet.
